Immunoglobulin heavy chain variable region (IGHV)

The Immunoglobulin heavy chain variable (IGHV) region is the N-terminal domain of the antibody heavy chain, which, together with the light chain variable region, forms the antigen-binding site or paratope [1][5]. It is encoded by a large multigene locus that undergoes V(D)J recombination and somatic hypermutation to generate a vast diversity of antigen specificities within the B-cell repertoire [1]. In clinical oncology, the IGHV region serves as a critical biomarker; for instance, the mutational status of IGHV in chronic lymphocytic leukemia (CLL) is a primary prognostic indicator [2][3]. Patients with unmutated IGHV (less than 2% deviation from germline) typically experience a more aggressive disease course and poorer response to certain chemoimmunotherapies compared to those with mutated IGHV [3]. While not a traditional drug target for broad-spectrum small molecules, the unique IGHV sequence of a patient's malignant B-cell clone (the idiotype) serves as a highly specific neoantigen for personalized immunotherapy, such as idiotype vaccines [4]. These vaccines aim to stimulate the patient's immune system to recognize and destroy B-cells expressing that specific variable region [4]. Additionally, the structural characteristics of certain IGHV genes can influence the binding affinity of therapeutic antibodies or the autoreactivity of B-cells in autoimmune conditions [5]. Sources: [1] Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2016. [2] Gaidano G, et al. J Clin Invest. 2012;122(10):3432-3438. [3] Hamblin TJ, et al. Blood. 1999;94(6):1848-1854. [4] Bendandi M. Nat Rev Cancer. 2009;9(9):671-681. [5] Schroeder HW Jr, Cavacini L. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-S52.

Other names

VH regionImmunoglobulin heavy variableVariable heavy chainIGHV regionAntibody heavy chain variable domain

Induction of idiotype-specific immune response via active vaccination targeting the unique variable region of the B-cell receptor to eliminate malignant clones.